The North America cancer tissue diagnostics market is expected to reach US$ 1,587.38 Mn in 2027 from US$ 923.79 Mn in 2018. The market is estimated to grow with a CAGR of 6.5% from 2019-2027.
The growth of the market is driven by the factors such as, growing cancer prevalence in North American region and new product launches & FDA approvals. However, the market is likely to slower down its growth due to the lack of reimbursement policies for cancer diagnosis in the region.
Frequent FDA approvals and product launches fuel the growth of the market for cancer tissue diagnostics. Most of the major market players are involved in the manufacturing wide range of cancer diagnostics products that offer maximum advantages and early diagnosis. For instance, in June 2019, Agilent Technologies Inc. received the U.S. Food and Drug Administration (FDA) approval for its PD-L1 IHC 22C3 pharmDx assay. The assay is approved to aim in identifying patients with head and neck squamous cell carcinoma (HNSCC) for treatment with KEYTRUDA (pembrolizumab), anti-PD-1 therapy manufactured by Merck. Furthermore, In March 2018, Agilent Technologies Inc. launched a new color for immunohistochemistry: HRP Magenta for Dako Omnis. The latest staining characteristics of the chromogen will help it for the assessment of skin and lung tissue. Thus, the constant developments in technology in diagnostics along with, FDA approvals accelerate the market growth during the forecast period.
US is expected to lead the market in the North America region owing to increasing prevalence of cancer, improved diagnosis and treatment of the condition along with the advancements made by market players. Moreover, the country has several hospitals, super specialty hospitals which offers diagnostic and treatment services for the cardiovascular diseases. Therefore, considering the above mentioned factors the growth of the market in the country is likely to contribute largest share in the North America region during the forecast period.
- This FREE sample will include data analysis, ranging from market trends to estimates and forecasts.
NORTH AMERICA CANCER TISSUE DIAGNOSTICS – MARKET SEGMENTATION
By Test Type
- Immunohistochemical Tests
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Stomach Cancer
- Others
- In Situ Hybridization Tests
- Breast Cancer
- Lung Cancer
- Bladder Cancer
- Others
Company Profiles
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
- Bio Rad Laboratories Inc.
- Abbott
- Enzo Life Sciences, Inc.
- Agilent Technologies, Inc.
- Cancer Genetics Inc.
- Merck KGaA (Sigma-Aldrich Co. LLC)
- Danaher Corporation
- Abcam plc
North America Cancer Tissue Diagnostics Report Scope
Report Attribute | Details |
---|---|
Market size in 2018 | US$ 923.79 Million |
Market Size by 2027 | US$ 1,587.38 Million |
Global CAGR (2019 - 2027) | 6.5% |
Historical Data | 2016-2017 |
Forecast period | 2019-2027 |
Segments Covered |
By Test Type
|
Regions and Countries Covered | North America
|
Market leaders and key company profiles |
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Testimonials

I wish to appreciate your support and the professionalism you displayed in the course of attending to my request for information regarding to infectious disease IVD market in Nigeria. I appreciate your patience, your guidance, and the fact that you were willing to offer a discount, which eventually made it possible for us to close a deal. I look forward to engaging The Insight Partners in the future, all thanks to the impression you have created in me as a result of this first encounter.
DR CHIJIOKE ONYIA, MANAGING DIRECTOR, PineCrest Healthcare Ltd.
The Insight Partners delivered insightful, well-structured market research with strong domain expertise. Their team was professional and responsive throughout. The user-friendly website made accessing industry reports seamless. We highly recommend them for reliable, high-quality research services
Yukihiko Adachi CEO, Deep Blue, LLC.Reason to Buy
- Informed Decision-Making
- Understanding Market Dynamics
- Competitive Analysis
- Customer Insights
- Market Forecasts
- Risk Mitigation
- Strategic Planning
- Investment Justification
- Identifying Emerging Markets
- Enhancing Marketing Strategies
- Boosting Operational Efficiency
- Tracking Industry Innovations
- Aligning with Regulatory Trends
Yes! We provide a free sample of the report, which includes Report Scope (Table of Contents), report structure, and selected insights to help you assess the value of the full report. Please click on the "Download Sample" button or contact us to receive your copy.
Absolutely — analyst assistance is part of the package. You can connect with our analyst post-purchase to clarify report insights, methodology or discuss how the findings apply to your business needs.
Once your order is successfully placed, you will receive a confirmation email along with your invoice.
• For published reports: You’ll receive access to the report within 4–6 working hours via a secured email sent to your email.
• For upcoming reports: Your order will be recorded as a pre-booking. Our team will share the estimated release date and keep you informed of any updates. As soon as the report is published, it will be delivered to your registered email.
We offer customization options to align the report with your specific objectives. Whether you need deeper insights into a particular region, industry segment, competitor analysis, or data cut, our research team can tailor the report accordingly. Please share your requirements with us, and we’ll be happy to provide a customized proposal or scope.
The report is available in either PDF format or as an Excel dataset, depending on the license you choose.
The PDF version provides the full analysis and visuals in a ready-to-read format. The Excel dataset includes all underlying data tables for easy manipulation and further analysis.
Please review the license options at checkout or contact us to confirm which formats are included with your purchase.
Our payment process is fully secure and PCI-DSS compliant.
We use trusted and encrypted payment gateways to ensure that all transactions are protected with industry-standard SSL encryption. Your payment details are never stored on our servers and are handled securely by certified third-party processors.
You can make your purchase with confidence, knowing your personal and financial information is safe with us.
Yes, we do offer special pricing for bulk purchases.
If you're interested in purchasing multiple reports, we’re happy to provide a customized bundle offer or volume-based discount tailored to your needs. Please contact our sales team with the list of reports you’re considering, and we’ll share a personalized quote.
Yes, absolutely.
Our team is available to help you make an informed decision. Whether you have questions about the report’s scope, methodology, customization options, or which license suits you best, we’re here to assist. Please reach out to us at sales@theinsightpartners.com, and one of our representatives will get in touch promptly.
Yes, a billing invoice will be automatically generated and sent to your registered email upon successful completion of your purchase.
If you need the invoice in a specific format or require additional details (such as company name, GST, or VAT information), feel free to contact us, and we’ll be happy to assist.
Yes, certainly.
If you encounter any difficulties accessing or receiving your report, our support team is ready to assist you. Simply reach out to us via email or live chat with your order information, and we’ll ensure the issue is resolved quickly so you can access your report without interruption.















The List of Companies
- F. Hoffmann-La Roche Ltd
- Thermo Fisher Scientific Inc.
- Bio Rad Laboratories Inc.
- Abbott
- Enzo Life Sciences, Inc.
- Agilent Technologies, Inc.
- Cancer Genetics Inc.
- Merck KGaA (Sigma-Aldrich Co. LLC)
- Danaher Corporation
- Abcam plc


